0001209191-22-051390.txt : 20220927 0001209191-22-051390.hdr.sgml : 20220927 20220927192009 ACCESSION NUMBER: 0001209191-22-051390 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220926 FILED AS OF DATE: 20220927 DATE AS OF CHANGE: 20220927 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dalal Anupam CENTRAL INDEX KEY: 0001602474 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38560 FILM NUMBER: 221272500 MAIL ADDRESS: STREET 1: 88 KEARNY STREET, SUITE 1800 CITY: SAN FRANCISCO STATE: CA ZIP: 94108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aadi Bioscience, Inc. CENTRAL INDEX KEY: 0001422142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 BUSINESS PHONE: 424-473-8055 MAIL ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 FORMER COMPANY: FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20170316 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP II DATE OF NAME CHANGE: 20071227 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-26 0 0001422142 Aadi Bioscience, Inc. AADI 0001602474 Dalal Anupam C/O AADI BIOSCIENCE, INC. 17383 SUNSET BOULEVARD, SUITE A250 PACIFIC PALISADES CA 90272 1 0 0 0 Common Stock 2022-09-26 4 A 0 320000 12.50 A 1849402 I See footnote Common Stock 1130 D Consists of (i) 1,572,698 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 276,704 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein. /s/ Stephen Rodin, as Attorney-in-Fact 2022-09-27